HUVEPHARMA®

Tilmovet® 30%

TILMICOSIN INJECTION

FOR CATTLE AND SHEEP

TILMOVET® 30% INJECTABLE

Composition

Active substance: **Tilmicosin 30%**

Tilmovet® 30% Injection is a sterile solution containing 30% tilmicosin. Tilmicosin is a semi-synthetic antibiotic of the macrolide class. It has been shown to be active *in vitro* mainly against Gram+ organisms (*Streptococci, Staphylococci*) and some Gram− microorganisms (*Pasteurella spp, Mannheimia haemolytica*), as well as against *Mycoplasma spp*.

Pharmaceutical form

Injection

Target species

Cattle, sheep

Indications

For use in cattle for the treatment of bovine respiratory disease (BRD) associated with *Mannheimia (Pasteurella) haemolytica* and *Pasteurella multocida*, and other organisms sensitive to tilmicosin.
For the treatment of footrot in sheep.

Practical dosing and administration

- Inject only subcutaneously in the anterior half of the neck.

Cattle

- For BRD, administer a single subcutaneous dose of 10 mg/kg of body weight (1 ml per 30 kg). Do not inject more than 15 ml per injection site.

Sheep

- For footrot, administer a single subcutaneous dose of 5 mg/kg of body weight (1 ml per 60 kg). Do not treat lambs weighing less than 15 kg.

Ensure the animal is properly restrained to reduce the risk of accidental self-injection. If no improvement is noted within 48 hours, the diagnosis should be re-evaluated.

Pharmacology

- Tilmicosin, 20-deoxo-20-(3,5-dimethylpiperidin-1-yl)-desmycosin is a chemically modified long-acting macrolide antibiotic. A single subcutaneous dose of tilmicosin at 10 mg/kg bodyweight reached maximal blood tilmicosin levels in one hour, and maintained therapeutic concentrations in the target tissues for at least three days. It is concentrated in the lungs, penetrating intracellularly in the alveolar macrophages.

Caution

The safety of tilmicosin has not been established in pregnant cattle or in animals used for breeding purposes. Intramuscular injection will cause a local reaction that may result in trim loss.

Contraindications

Intravenous injection in cattle may be fatal. Injection has been shown to be fatal in swine, non-human primates, goats and lambs less than 15 kg bodyweight and it may be fatal in horses.

Withdrawal period(s)

- **Meat**:
  Cattle: 28 days of last treatment
  Sheep: 42 days of last treatment

- **Milk**:
  Milk intended for sale for human consumption must be discarded during treatment and for not less than 35 days following the last treatment.

Packaging

- The product is presented in glass vials from 25, 50 and 100 ml. Type II colourless glass vials, sealed with a bromobutyl stopper and aluminium cap supplied in a carton. One vial per carton.
- Not all pack sizes may be marketed



WARNING

May be harmful if swallowed.
Causes skin irritation. Causes eye irritation.
Very toxic to aquatic life. Harmful to terrestrial vertebrates.
Wear protective gloves. Take off contaminated clothing and wash before reuse. Wash hands and exposed skin thoroughly after handling. Do not eat, drink or smoke when using this product.
If on skin: wash with plenty of soap and water. If skin irritation occurs, get medical advice or attention.
If in eyes: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice/attention.
If medical advice is needed, have product container or label at hand.
Injection in humans has been associated with fatalities. Exercise extreme caution to avoid accidental self-injection. Do not work alone when using Tilmovet®. Do not use in automatically powered injectors or syringes. Do not carry a syringe loaded with Tilmovet ® with the needle attached, except for filling the syringe or for administration to the animal. Remove needle at all other times. In case of human injection, consult a physician immediately and apply ice or cold pack to the injection site.

Tilmovet®

Tilmovet.30%.Inj.0217.EN01/Novis

HUVEPHARMA®

HUVEPHARMA EOOD • 3A NIKOLAY HAYTOV STR • 1113 SOFIA • **BULGARIA** • P +359 2 862 5331 • F +359 2 862 5334 • SALES@HUVEPHARMA.COM
HUVEPHARMA N.V. • UITBREIDINGSTRAAT 80 • 2600 ANTWERP • **BELGIUM** • P +32 3 288 1849 • F +32 3 289 7845 • CUSTOMERSERVICE@HUVEPHARMA.COM